Robeco Institutional Asset Management B.V. Sells 15,595 Shares of Becton, Dickinson and Company $BDX

Robeco Institutional Asset Management B.V. lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 51.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,508 shares of the medical instruments supplier’s stock after selling 15,595 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Becton, Dickinson and Company were worth $2,715,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. SOA Wealth Advisors LLC. increased its position in Becton, Dickinson and Company by 256.8% in the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the period. Bell Investment Advisors Inc lifted its holdings in Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 128 shares during the period. Bank of Jackson Hole Trust boosted its stake in Becton, Dickinson and Company by 85.6% in the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 95 shares during the last quarter. CVA Family Office LLC grew its holdings in Becton, Dickinson and Company by 79.5% during the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 97 shares during the period. Finally, CoreFirst Bank & Trust bought a new stake in Becton, Dickinson and Company in the second quarter valued at about $38,000. 86.97% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 629 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total value of $123,302.87. Following the sale, the executive vice president directly owned 13,105 shares of the company’s stock, valued at $2,568,973.15. This represents a 4.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 1,052 shares of company stock worth $201,235. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $202.78 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The firm has a fifty day simple moving average of $193.11 and a 200 day simple moving average of $188.24. The stock has a market capitalization of $57.77 billion, a PE ratio of 34.78, a P/E/G ratio of 2.24 and a beta of 0.23. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were issued a $1.05 dividend. The ex-dividend date of this dividend was Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.1%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is currently 72.04%.

Analyst Ratings Changes

BDX has been the subject of a number of recent analyst reports. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday. Argus boosted their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Jefferies Financial Group lifted their target price on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Morgan Stanley raised their price target on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Four equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $207.64.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.